SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000920465-20-000119
Filing Date
2020-07-29
Accepted
2020-07-28 17:36:29
Documents
4
Period of Report
2020-07-28
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ljpc-ttphclosing8xk_72820x.htm 8-K 44647
2 EXHIBIT 10.1 ljpc_tetraphase-cvragreeme.htm EX-10.1 166566
3 ljpctetraphasecvragre_image1.gif GRAPHIC 33130
4 ljpctetraphasecvragre_image2.gif GRAPHIC 4663
  Complete submission text file 0000920465-20-000119.txt   264857
Mailing Address 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Business Address 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36282 | Film No.: 201054900
SIC: 2836 Biological Products, (No Diagnostic Substances)